ライフサイエンスコーパス: thrombotic thrombocytopenic purpura

1 timeric strings secreted by/anchored to ECs (thrombotic thrombocytopenic purpura).

2 y as an effective means of treating acquired thrombotic thrombocytopenic purpura.

3 whereas too much platelet adhesion may cause thrombotic thrombocytopenic purpura.

4 roaches to refractory and relapsing cases of thrombotic thrombocytopenic purpura.

5 ia; the pathophysiology differs from that of thrombotic thrombocytopenic purpura.

6 ients with refractory and relapsing acquired thrombotic thrombocytopenic purpura.

7 DAMTS13 deficiency causes a lethal syndrome, thrombotic thrombocytopenic purpura.

8 enesis of congenital and acquired idiopathic thrombotic thrombocytopenic purpura.

9 ibited by IgG from a patient with idiopathic thrombotic thrombocytopenic purpura.

10 n, pathophysiology and current management of thrombotic thrombocytopenic purpura.

11 the catastrophic microangiopathic disorder, thrombotic thrombocytopenic purpura.

12 tor-cleaving metalloprotease ADAMTS13 causes thrombotic thrombocytopenic purpura.

13 adults whose illnesses also met criteria for thrombotic thrombocytopenic purpura.

14 mulation of large multimers, which may cause thrombotic thrombocytopenic purpura.

15 grel for 14 days or less before the onset of thrombotic thrombocytopenic purpura.

16 eaving protease occur in patients with acute thrombotic thrombocytopenic purpura.

17 coagulation, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

18 c value for Adamts13(-/-) mice in a model of thrombotic thrombocytopenic purpura.

19 itory antibodies against ADAMTS13 that cause thrombotic thrombocytopenic purpura.

20 core antigenic target for autoantibodies in thrombotic thrombocytopenic purpura.

21 of ADAMTS13, a condition only experienced in thrombotic thrombocytopenic purpura.

22 ome (aHUS), while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura.

23 ma DNA and MPO were characteristic for acute thrombotic thrombocytopenic purpura.

24 nd life-threatening disorder called acquired thrombotic thrombocytopenic purpura.

25 SCD to other microangiopathies, particularly thrombotic thrombocytopenic purpura.

26 ADAMTS13, a plasma metalloprotease, leads to thrombotic thrombocytopenic purpura.

27 actor (VWF)-cleaving metalloprotease, causes thrombotic thrombocytopenic purpura.

28 iciency alone may not be sufficient to cause thrombotic thrombocytopenic purpura.

29 mage: atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

30 ency of ADAMTS13 activity in plasma leads to thrombotic thrombocytopenic purpura.

31 hould further clarify its role in idiopathic thrombotic thrombocytopenic purpura.

32 Thrombotic thrombocytopenic purpura, a clinical syndrome

33 ars revealed a molecular distinction between thrombotic thrombocytopenic purpura, a disease character

34 retion by human endothelial cells and causes thrombotic thrombocytopenic purpura, a disease with simi

35 Thrombotic thrombocytopenic purpura, a life-threatening

36 During therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs o

37 Dsg1, we cloned mAbs from two patients with thrombotic thrombocytopenic purpura and a healthy person

38 Third, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockou

39 thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic

40 the association between ticlopidine use and thrombotic thrombocytopenic purpura and other adverse ef

41 13 and help us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial t

42 DAMTS13 could be an antithrombotic agent for thrombotic thrombocytopenic purpura and other thrombotic

43 I in microvascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revea

44 ADAMTS13 immunoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignme

45 ical conditions including arthritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlo

46 d its look-alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic ur

47 Mutations from thrombotic thrombocytopenic purpura and von Willebrand d

48 spherocytosis, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and others.

49 microangiopathy and a possible diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004,

50 n proved to be the most important therapy in thrombotic thrombocytopenic purpura, but clinical data f

51 such as atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense dep

52 Thrombotic thrombocytopenic purpura can occur after the

53 peutic plasma exchange in some patients with thrombotic thrombocytopenic purpura; conversely such def

54 By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cl

55 Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodi

56 d laboratory findings in 11 patients in whom thrombotic thrombocytopenic purpura developed during or

57 rand factor and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relat

58 Thrombotic thrombocytopenic purpura exemplifies how von

59 amples of plasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficienc

60 tanding of the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the ra

61 mbine to increase the risk for occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syn

62 gnancy with greatest risk for development of thrombotic thrombocytopenic purpura-hemolytic uremic syn

63 insufficiency, making their distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syn

64 Thrombotic thrombocytopenic purpura-hemolytic uremic syn

65 Case series of thrombotic thrombocytopenic purpura-hemolytic uremic syn

66 (1) to document the reports of occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syn

67 reports of women with congenital or familial thrombotic thrombocytopenic purpura-hemolytic uremic syn

68 Initial management of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syn

69 Thrombotic thrombocytopenic purpura-hemolytic uremic syn

70 Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syn

71 Thrombotic thrombocytopenic purpura-hemolytic uremic syn

72 We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syn

73 to distinguish aHUS from other TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioa

74 N (vasculitis), 6; hemolytic uremic syndrome-thrombotic thrombocytopenic purpura (HUS/TTP), 8; system

75 ad been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients.

76 d in 16 samples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 7

77 ADAMTS13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threa

78 ombocytopenia, antiphospholipid syndrome and thrombotic thrombocytopenic purpura, include immunosuppr

79 cytopenia in patients with acute episodes of thrombotic thrombocytopenic purpura, independent of ADAM

80 stimated incidence of ticlopidine-associated thrombotic thrombocytopenic purpura is 1 per 1600 to 500

81 Thrombotic thrombocytopenic purpura is a potentially fat

82 Thrombotic thrombocytopenic purpura is a rare complicati

83 Thrombotic thrombocytopenic purpura is associated with a

84 The acquired form of thrombotic thrombocytopenic purpura is associated with i

85 Thrombotic thrombocytopenic purpura is caused by congeni

86 The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to pred

87 characterised by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by

88 actor-cleaving protease activity in acquired thrombotic thrombocytopenic purpura is due to an autoant

89 ultaneous pancreas/kidney (SPK)] developed a thrombotic thrombocytopenic purpura-like clinical syndro

90 Several systemic diseases, including thrombotic thrombocytopenic purpura, manifest much of th

91 glycemia (n = 27), neurotoxicity (n = 9) and thrombotic thrombocytopenic purpura (n = 2).

92 13 to make management decisions in suspected thrombotic thrombocytopenic purpura, new evidence suppor

93 erstanding of the pathological mechanisms of thrombotic thrombocytopenic purpura not only provide a r

94 protease in plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other

95 nge continues to be indicated for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS

96 turally occurring in patients with inherited thrombotic thrombocytopenic purpura, resulted in a signi

97 erturbation associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabete

98 In thrombotic thrombocytopenic purpura, the clinical impact

99 y of this protease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombos

100 Thrombotic thrombocytopenic purpura (TTP) affects 1 in 1

101 Thrombotic thrombocytopenic purpura (TTP) and hemolytic

102 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic

103 iopathy, which includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic

104 Thrombotic thrombocytopenic purpura (TTP) and sporadic h

105 Thrombotic thrombocytopenic purpura (TTP) and the hemoly

106 Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears comple

107 r triggers leading to idiopathic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying

108 The pathophysiology of thrombotic thrombocytopenic purpura (TTP) can be explain

109 t cases of haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Esch

110 Thrombotic thrombocytopenic purpura (TTP) has been a mys

111 Thrombotic thrombocytopenic purpura (TTP) in adults is u

112 Thrombotic thrombocytopenic purpura (TTP) is a devastati

113 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-thre

114 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

115 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

116 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-thre

117 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

118 Thrombotic thrombocytopenic purpura (TTP) is a microangi

119 Thrombotic thrombocytopenic purpura (TTP) is a rare and

120 Thrombotic thrombocytopenic purpura (TTP) is a rare and

121 Gemcitabine-associated thrombotic thrombocytopenic purpura (TTP) is a rare comp

122 Thrombotic thrombocytopenic purpura (TTP) is a syndrome

123 Idiopathic thrombotic thrombocytopenic purpura (TTP) is a thromboti

124 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by a

125 Acquired thrombotic thrombocytopenic purpura (TTP) is characteriz

126 The pathogenesis of thrombotic thrombocytopenic purpura (TTP) is obscure.

127 Thrombotic thrombocytopenic purpura (TTP) is primarily c

128 Thrombotic thrombocytopenic purpura (TTP) is the common

129 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequ

130 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, b

131 id syndrome (APS), atypical presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-ind

132 al plasmatic ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is co

133 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no a

134 vity in normal plasma, and its deficiency in thrombotic thrombocytopenic purpura (TTP) patients, prov

135 Although both aHUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinica

136 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery

137 eficiency of plasma ADAMTS13 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threat

138 se, is the key factor in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threat

139 In thrombotic thrombocytopenic purpura (TTP), a multimeric

140 change is an effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how thera

141 Pregnancy may precipitate acute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy

142 Recent advances have demonstrated that thrombotic thrombocytopenic purpura (TTP), characterized

143 cy is linked to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized

144 its associated with platelet transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induc

145 erentiating aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult

146 ) to treat immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively,

147 are the hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories

148 In acquired thrombotic thrombocytopenic purpura (TTP), the persisten

149 y of this metalloprotease is associated with thrombotic thrombocytopenic purpura (TTP).

150 inhibit the activity of the protease, causes thrombotic thrombocytopenic purpura (TTP).

151 ascular thrombosis in patients with acquired thrombotic thrombocytopenic purpura (TTP).

152 AMTS13 is associated with the development of thrombotic thrombocytopenic purpura (TTP).

153 onsible for systemic platelet aggregation in thrombotic thrombocytopenic purpura (TTP).

154 ivity leads to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

155 13 (ADAMTS13) revolutionized our approach to thrombotic thrombocytopenic purpura (TTP).

156 Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP).

157 MTS13 deficiency to complement activation in thrombotic thrombocytopenic purpura (TTP).

158 nd life-threatening disorder called acquired thrombotic thrombocytopenic purpura (TTP).

159 ies with hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

160 MTS13 deficiency leads to the fatal disorder thrombotic thrombocytopenic purpura (TTP).

161 es in attempts to ameliorate the symptoms of thrombotic thrombocytopenic purpura (TTP).

162 plays a crucial role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP).

163 y a rare but life-threatening disease called thrombotic thrombocytopenic purpura (TTP).

164 inhibition of this enzyme activity leads to thrombotic thrombocytopenic purpura (TTP).

165 on between severe deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

166 ivity leads to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

167 volutionized our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP).

168 characteristic of idiopathic and HIV-linked thrombotic thrombocytopenic purpura (TTP).

169 t of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP).

170 central role in pathogenesis of the disease thrombotic thrombocytopenic purpura (TTP); however, expe

171 e study of TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry wi

172 se may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 mo

173 Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.

174 A more common TMA is thrombotic thrombocytopenic purpura, which is caused by

175 tease inhibitors, and the risk of relapse of thrombotic thrombocytopenic purpura will be important to